Limitless Pharma (0802.144.864): annual accounts and directors

Limitless Pharma

Antwerp ·KBO/BCE: BE 0802.144.864

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Group	Expected	Actual
1	0.2%	0.2%
2	0.3%	0.5%
3	0.5%	0.6%
4	0.7%	0.8%
5	0.9%	0.9%
6	1.3%	1.5%
7	1.6%	1.8%
8	1.8%	1.8%
9	3.0%	3.1%
10	5.6%	6.2%

Company
Limitless Pharma Antwerp	€22,449	-€18,071	-102.1%	-
POINT COMMERCE Antwerp	€21,907	€704	-77.0%	-
OUTMANA Malle	€17,298	-€4,699	-195.9%	-
Felicidad Antwerp Malle	€29,591	€1,041	15.2%	-
Diversita Mol	€29,939	-€5,077	54.0%	-
TOINETTE Mouscron	€18,778	-€19,125	-143.0%	-
BOBBIE BAHAMA Ghent	€19,272	-€5,116	-63.5%	-

Line	2025	2024
Balance sheet: assets
`20/58`	22,449	22,671
`21/28`	4,741	5,272
`21`	4,741	5,272
`29/58`	17,708	17,400
`3`	13,271	13,271
`30/36`	13,271	13,271
`40/41`	3,230	1,576
`41`	3,230	1,576
`54/58`	1,208	2,553
Balance sheet: equity and liabilities
`10/49`	22,449	22,671
`10/15`	-22,918	-9,314
`10/11`	7,000	2,000
`14`	-29,918	-11,314
`17/49`	45,367	31,985
`17`	27,600	27,600
`170/4`	27,600	27,600
`42/48`	17,767	4,385
`43`	42	-
`430/8`	42	-
`44`	2,029	4,268
`440/4`	2,029	4,268
`45`	0	51
`450/3`	0	51
`47/48`	15,696	66
Income statement
`9900`	-18,071	-10,186
`630`	531	39
`640/8`	120	890
`9901`	-18,722	-11,115
`75/76B`	369	20
`75`	369	20
`65/66B`	251	219
`65`	251	219
`9903`	-18,605	-11,314
`9904`	-18,605	-11,314
`9905`	-18,605	-11,314
Appropriation of the result
`9906`	-29,918	-11,314
`14P`	-11,314	-
Document	PDF	PDF

Financial year	Type	Filed	Reference	Document
31-12-2025	micro format	29-09-2026	2026-00530380	PDF
31-12-2024	micro format	23-07-2025	2025-00297402	PDF

Line	Trend	2025	2024
		-18,191	-11,075
		-18,074	-11,274
		0	5,311
		-1,346	-
		-59	13,015
		-102.1%	-41.1%
		1.00	3.97
		0.25	0.94
		-82.9%	-49.9%
		-72.40	-50.52

Item	2025	2024
Intangible fixed assets	-	€5,311
	€531	€39

Overview

Lifetime

Key points

Equity

Losses

Debts

Liquidity

Board

Position in the sector

Checked score

Score breakdown

Comparable companies, two years later

Credit verdict

Signals

Board and ownership

Recent changes

Comparable companies

Official details

Annual accounts 2025

Insights on Limitless Pharma

Financials

Annual accounts 2025

Balance sheet

Change in equityin euro

Change in cashin euro

Position in the sector

Solvency-102.1%

Current ratio1.00

Return on assets-82.9%

Filed annual accounts

Filings

Key figures and ratios

Investments

Insights on Limitless Pharma

Board & ownership

Board

Mandates through the years

Control

Capital

Articles of association

Founders

Network & group

No group

At the same address

Timeline

Timeline

History

Company details

Identity

Activities

Registered office and establishments

Buildings and parcels at the address

Location

Parcels

in euro

in euro

-102.1%

1.00

-82.9%